Overweight is Associated with Impaired Beta-cell Function During Pregnancy: a Longitudinal Study of 553 Normal Pregnancies
Overview
Affiliations
Objective: To monitor beta-cell function and insulin sensitivity longitudinally in a large cohort of pregnant women to elucidate mechanisms that influence glycemic control in pregnancy.
Design And Methods: Five hundred and fifty-three pregnant Scandinavian women underwent 75 g oral glucose tolerance test (OGTT) at weeks 14-16 and 30-32. Insulin sensitivity (Matsuda index) and beta-cell function (ratio of AUC(insulin) to AUC(glucose), AUC(ins/glc)) were calculated from 520 complete tests, and subsequently beta-cell function was adjusted for insulin sensitivity, rendering an oral disposition index (DI(o)).
Results: Eleven women (2.1%) had gestational diabetes mellitus (GDM1) at weeks 14-16, and 49 (9.4%) at weeks 30-32 (GDM2), which is higher than that previously reported in this region. In the subdivision of OGTT, more overweight (body mass index>25) was found in glucose-intolerant groups (glucose-tolerant women (normal glucose tolerance, NGT) 38 versus GDM2 women 58 and GDM1 women 82%, P<0.005). In early pregnancy, insulin sensitivity was lowest in GDM1, intermediate in GDM2, and highest in NGT. In late pregnancy, insulin sensitivity decreased in all groups, most in gestational diabetes. beta-cell function demonstrated minor shifts during pregnancy, but when adjusted for decreasing insulin sensitivity, DI(o) levels fell by 40% (P<0.001). DI(o) was significantly attenuated relative to glucose intolerance (GDM1 25% and GDM2 53%) during pregnancy. In overweight women, DI(o) levels were lower throughout pregnancy (P<0.001 versus normal weight women), this reduction was significant (P<0.01) in both NGT (21-25%) and GDM2 subjects (26-49%).
Conclusion: beta-cell function adjusted for insulin sensitivity (DI(o)) deteriorated during pregnancy in both glucose-tolerant and glucose-intolerant women. The failure to compensate the decrease in insulin sensitivity was accentuated in overweight women.
Tagami K, Iwama N, Hamada H, Tomita H, Kudo R, Kumagai N J Diabetes Investig. 2024; 15(6):751-761.
PMID: 38391358 PMC: 11143417. DOI: 10.1111/jdi.14159.
Kristiansen O, Roland M, Zucknick M, Reine T, Kolset S, Henriksen T J Endocrinol Invest. 2022; 45(11):2105-2121.
PMID: 35781790 PMC: 9525437. DOI: 10.1007/s40618-022-01842-2.
Roland M, Lekva T, Godang K, Bollerslev J, Henriksen T PLoS One. 2020; 15(6):e0232749.
PMID: 32574162 PMC: 7310681. DOI: 10.1371/journal.pone.0232749.
Lekva T, Godang K, Michelsen A, Qvigstad E, Normann K, Norwitz E Sci Rep. 2018; 8(1):13392.
PMID: 30190548 PMC: 6127333. DOI: 10.1038/s41598-018-31614-z.
Bozkurt L, Gobl C, Pfligl L, Leitner K, Bancher-Todesca D, Luger A J Clin Endocrinol Metab. 2015; 100(3):1113-20.
PMID: 25574889 PMC: 4333043. DOI: 10.1210/jc.2014-4055.